GP
REGN icon

GLG Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

GLG Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,463
Closed -$4.7M – 444
2014
Q4 		$4.7M Sell
11,463
-4,439
-28% -$1.75M 0.14% 169
2014
Q3 		$5.73M Buy
+15,902
New +$5.33M 0.13% 192

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GLG Partners's REGN Position: Q1 2015 in Review

GLG Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2015, closing a stake of 11,463 shares — an estimated $4.7M sold.

GLG Partners first reported a position in REGN in Q3 2014 and held it in 2 quarters. The position peaked at $5.73M in Q3 2014. 508 funds tracked by Wall St. Rank hold REGN as of Q1 2015.

  • GLG Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • GLG Partners sold 11,463 Regeneron Pharmaceuticals shares in Q1 2015, an estimated $4.7M.
  • GLG Partners first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • GLG Partners's Regeneron Pharmaceuticals position peaked at $5.73M in Q3 2014.
  • 508 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2015.

Based on GLG Partners's 13F filing for Q1 2015, filed 15 May 2015.